It's time to phase out “serologic weak D phenotype” and resolve D types with <i>RHD</i> genotyping including weak D type 4
Willy A. Flegel(National Institutes of Health Clinical Center), S. Gerald Sandler(Georgetown University), Gregory A. Denomme(Grifols (United States)), Ralph R. Vassallo(Vitalant), Connie M. Westhoff(New York Blood Center), Meghan Delaney(Children's National), John T. Queenan(Georgetown University), Clayton D. Simon, Margaret Keller(American Red Cross), Susan T. Johnson(Versiti Blood Center of Wisconsin), Louis M. Katz
Cited by 56
Related Papers
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k
Red Blood Cell Transfusion: A Clinical Practice Guideline From the AABB*
|Annals of Internal Medicine|2012|1.1k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863
Effects of Red-Cell Storage Duration on Patients Undergoing Cardiac Surgery
|New England Journal of Medicine|2015|486
Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region
|The Journal of Pediatrics|2020|373